Incyte Corp. (INCY) announced Thursday morning that its Phase 3 study of baricitinib met its primary endpoint of improved ACR 20 response compared to placebo. Baricitinib is a treatment for moderate-to-severe rheumatoid arthritis.
from RTT - Before the Bell http://ift.tt/1MZikPZ
via IFTTT
No comments:
Post a Comment